Elanco Animal Health Inc

NYSE:ELAN   4:00:00 PM EDT
12.57
-0.28 (-2.18%)
Other Pre-Announcement

Elanco Animal Health Reports Third Quarter 2022 Results

Published: 11/08/2022 12:31 GMT
Elanco Animal Health Inc (ELAN) - Elanco Animal Health Reports Third Quarter 2022 Results.
Q3 Loss per Share $0.10.
Q3 Adjusted Earnings per Share $0.20.
Q3 Revenue Fell 9 Percent to $1.028 Billion.
Sees FY Revenue of $4,385 to $4,430 Million.
Sees FY Reported Loss per Share of $0.17 to $0.12.
Sees FY Adjusted EPS of $1.01 to $1.07.
Q3 Earnings per Share View $0.16, Revenue View $1.03 Billion -- Refinitiv Ibes Data (analyst estimates).
FY2022 Earnings per Share View $1.08, Revenue View $4.49 Billion -- Refinitiv Ibes Data (analyst estimates).
Initiated Submission for Broad Spectrum Parasiticide to U.S. FDA With Approval Expected in 12 to 18 Months.
Elanco Animal Health - Expect Approval of First Sglt-2 Product for Feline Diabetes by Late 2022 Or Early 2023.
Elanco Animal Health - Expects Approval of First Conditional Approval of First Monoclonal Antibody Treatment for Parvovirus by Late 2022 Or Early 2023.